ClinicalTrials.gg
RecruitingNCT07580716Updated Oct 13, 2026

Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

A Phase 2 interventional study of Allocetra and Placebo in Primary Knee Osteoarthritis, sponsored by Enlivex Therapeutics Ltd.. Recruiting at 17 sites in 3 countries. Open to participants aged 64 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Enlivex Therapeutics Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 13, 2026Site recruiting status changedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
64 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Osteoarthritis with a site in Poland — 11 open to participants now, 12 under way, none of them phase 3. Osteoarthritis · Poland.

Planned enrollment
28th of 64
182 · median 121
Started
2026
with 4 others
Phase 2
15 of 71
3 open now
Primary completion
2027-02
later than 5 of 11 live
Registered
69th of 71
by date

Among the 71 studies in Osteoarthritis with a site in Poland, this one is the 28th largest by planned enrollment of the 64 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 in phase 2, reaches primary completion later than 5 of the 11 other live ones, and was the 69th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

11 of the 71 studies in Osteoarthritis with a site in Poland are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 64 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Osteoarthritis with a site in Poland, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).

Read the detailed description

Knee osteoarthritis is a degenerative disease driven by physical breakdown of the joint cartilage, together with a chronic inflammation within the knee space. Over time, many patients will develop worsening pain in the joint and functional impairment, which may ultimately require knee replacement.

Allocetra is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state.

The main goal of this Phase IIb clinical trial is to evaluate the efficacy of intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA), in comparison to Placebo (a look-alike substance that contains no drug). Participants will be randomized 1:1 to Allocetra or Placebo. Treatment consists of a total of three ultrasound-guided intra-articular (IA) injections (Days 0, 14, 28). Follow-up will continue for 12 months.

03

Conditions studied

  • Primary Knee Osteoarthritis

Browse trials for

Keywords

  • Knee
  • Osteoarthritis
  • Allocetra
04

Who can participate

Ages eligible
64 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the inclusion criteria listed below to be eligible for the study:

  1. Age 64 years or above.
  2. Diagnosis of primary femorotibial knee OA.
  3. Radiographic evidence of knee OA defined as Kellgren-Lawrence (KL) grade 2 or 3 in the index knee.
  4. Participants who are intolerant to, or have failed to adequately respond to at least 2 OA therapies.
  5. Index knee pain assessed during the screening period and following wash-out of pain medications.
  6. Willingness to abstain from prohibited medications/treatments during the trial.
  7. Women who are (≥12 months natural amenorrhea without alternative cause) or surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
  8. Male participants with partners of , who are not surgically sterile (vasectomy) for at least 6 months prior to randomization, must use condoms with spermicide in addition to their partner's from randomization and for 90 days after last dose.

Exclusion criteria

Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

  1. Severe or end-stage osteoarthritis of the index knee.
  2. structural abnormalities or instability of the index knee.
  3. Recent major injury, surgical procedure, or intra-articular treatment in the index knee.
  4. Any known history of infection or tumor of the index knee, or active infection at the intended injection site.
  5. Any known history of inflammatory arthropathy or crystal-deposition disease.
  6. Any severe systemic cartilage, bone, or musculoskeletal disorder that may interfere with study outcomes.
  7. Clinically significant widespread pain syndromes.
  8. therapy, clinically significant immunodeficiency, or active infection.
  9. (BMI) >40 kg/m²
  10. Use of medications that may interfere with pain assessment or study outcomes.
  11. Known coagulopathy or use of anticoagulant/antiaggregant medication.
  12. Significant uncontrolled systemic disease or clinically significant findings on screening laboratory tests or physical examination.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Allocetra

    Three intra-articular injections of Allocetra at a selected dose, into the index knee.

    Drug: Allocetra

  • Placebo comparator
    Placebo

    Three intra-articular injections of placebo into the index knee.

    Other: Placebo

Interventions

  • DrugAllocetra

    Allocetra is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state.

  • OtherPlacebo

    The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.

06

What researchers measure

Primary outcomes

  1. Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain score at 3 months

    The change from baseline of the WOMAC Pain score at 3 months between Allocetra and Placebo. Total Pain score ranges from 0 (No pain) to 50 (Extreme pain).

    Time frame: 3 months.

  2. Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function score at 3 months

    The change from baseline for the WOMAC Function score at 3 months between Allocetra and Placebo. Total Function score ranges from 0 (No difficulty) to 170 (Extreme difficulty).

    Time frame: 3 months.

  3. Primary Safety Endpoint

    Incidence and severity of Adverse Events (AEs) up to 6 months. AE incidence will be represented as % per study group and AE severity will be represented as mild, moderate or severe.

    Time frame: Day 0 to 6 months.

Secondary outcomes

  1. Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain score

    The change from baseline of the WOMAC Pain score at 6 months. Total Pain score ranges from 0 (No pain) to 50 (Extreme pain).

    Time frame: 6 months.

  2. Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function score

    The change from baseline of the WOMAC Function score at 6 months. Total Function score ranges from 0 (No difficulty) to 170 (Extreme difficulty).

    Time frame: 6 months.

  3. Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total score

    The change from baseline for the WOMAC Total score at 3 and 6 months. Total score ranges from 0 to 240 when higher score means worse outcomes.

    Time frame: 3 months, 6 months.

  4. Average Daily Pain Numerical Rating Scale (ADP-NRS)

    The change from baseline of the Average Daily Pain Numerical Rating Scale (ADP-NRS) at 3 and 6 months. ADP-NRS score ranges from 0 (No pain) to 10 (Worst imaginable pain).

    Time frame: 3 months, 6 months.

  5. Outcome Measures in Rheumatology and Osteoarthritis Research Society International (OMERACT-OARSI) score

    Treatment responders at 3 and 6 months according to the Outcome Measures in Rheumatology (OMERACT) and Osteoarthritis Research Society International (OARSI) criteria. OMERACT-OARSI score will be represented as % when higher scores means a better outcome.

    Time frame: 3 months, 6 months.

  6. Euro Quality of Life-5-Dimension (EQ-5D) index scores

    Change from baseline in Euro Quality of Life-5-Dimension (EQ-5D) index scores at 3 and 6 months. EQ-5D index scores in composed of an index value which range from 0 to 1 and EQ VAS score which range from 0 to 100. In both a higher score means better outcomes.

    Time frame: 3 months, 6 months.

07

Study locations

15 of 17 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 9 months is below that.

Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 12, 2026
StartActual
May 1, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Apr 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • NZOZ Bif-Med. s.c · Bytom, PolandNot yet recruiting→Recruiting
  • Vita Longa Sp. z o.o. · Katowice, PolandNot yet recruiting→Recruiting
  • Reumedika sp. z o.o. · Poznan, PolandNot yet recruiting→Recruiting
  • Etg Justmed · Warsaw, PolandNot yet recruiting→Recruiting
  • Migre Polskie Centrum · Wroclaw, PolandNot yet recruiting→Recruiting
Oct 13, 2026
Enrollment
270→182
Oct 13, 2026
Sponsor
Collaborators added: Nordic Bioscience Clinical Development; collaborators removed: Nordic Bioscience Clinical Development (NBCD)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • NZOZ Bif-Med. s.c · Bytom, PolandNot yet recruiting→Recruiting
    • Vita Longa Sp. z o.o. · Katowice, PolandNot yet recruiting→Recruiting
    • Reumedika sp. z o.o. · Poznan, PolandNot yet recruiting→Recruiting
    • Etg Justmed · Warsaw, PolandNot yet recruiting→Recruiting
    • Migre Polskie Centrum · Wroclaw, PolandNot yet recruiting→Recruiting
    Enrollment 270→182
    Sponsor Collaborators added: Nordic Bioscience Clinical Development; collaborators removed: Nordic Bioscience Clinical Development (NBCD)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07580716
Lead sponsor
Enlivex Therapeutics Ltd.
Collaborators
Nordic Bioscience Clinical Development
Responsible party
Sponsor
First posted
May 12, 2026
Start date
May 1, 2026
Primary completion
Feb 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Lior Binder
Contact
lior@enlivex.com
+972-54-8054599
Lital Weinfeld Bergman
Contact
lital@enlivex.com
Lital Weinfeld Bergman
study director · Senior Director of Clinical Operations

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion